Analysts Review, December 29, 2014 /PRNewswire/ --
Moments ago, Analysts Review released new research updates concerning several important developing situations including Coherus (NASDAQ: CHRS), Barrick Gold (NASDAQ: ABX), Atossa (NASDAQ: ATOS), Intersect ENT (NASDAQ: XENT), and Walgreens (NYSE: WAG). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CHRS Research Report: ( http://get.analystsreview.com/pdf/?c=Coherus&d=29-Dec-2014&s=CHRS ),
ABX Research Report: ( http://get.analystsreview.com/pdf/?c=Barrick%20Gold&d=29-Dec-2014&s=ABX ),
ATOS Research Report: ( http://get.analystsreview.com/pdf/?c=Atossa&d=29-Dec-2014&s=ATOS ),
XENT Research Report: ( http://get.analystsreview.com/pdf/?c= Intersect%20ENT&d=29-Dec-2014&s=XENT ),
WAG Research Report: ( http://get.analystsreview.com/pdf/?c=Walgreens&d=29-Dec-2014&s=WAG ).
============
--
Analyst Update: Financial Results, Shareholders' Vote, Appointments and Company Updates
Reviewed by: Rohit Tuli, CFA®
The U.S. stock market prolonged its winning streak on Friday, ending the day in green, as positive sentiments continued to buoy the markets after the Christmas holiday. The Dow Jones Industrial Average (DJIA) gained for seven consecutive trading days and ended the session at 18,053.71, up 0.13%, while the S&P 500 moved up 0.33% to 2088.77. The Nasdaq Composite advanced 0.70% and closed at 4,806.86, its highest level since March 2000. The European markets will remain close till Monday. The Asian stocks were mostly higher, as investors played down a slew of Japanese economic reports on inflation, industrial output and the labor market. The data showed that inflation in Japan was slowing, despite efforts of increasing it; however, the market reaction to the November figures was largely muted.
Coherus Biosciences Inc.'s (Coherus) losses for third quarter shrink, as the Company prepares for Phase III clinical development of CHS-1420 drug candidate. The quarter also saw Coherus receive two milestone payments aggregating $25.0 million under existing collaboration with Baxter Healthcare Corporation. Read our research report on Coherus to know more about the latest results and 2015 outlook.
The new taxation regime renders the Lumwana copper mine in Zambia unviable, says Barrick Gold Corporation (Barrick Gold). Consequently, the Company has decided to suspend its mining operations, although it remains hopeful of an alternative solution. What impact will the suspension have on Barrick Gold? Read our research report to know about the suspension and the potential repercussions on the Company.
Shares of Seattle-based biotech firm, Atossa Genetics Inc. (Atossa) rallied 31.47% to end the trading session at $1.88A, amidst high trading volumes. A total of 10.49 million shares changed hands, significant higher than the previous day's trading volume of 1.48 million shares. The shares of the Company have doubled in the last three trading sessions. Read our research report on Atossa to know more about the Company financials and latest developments.
Shares of Intersect ENT Inc (Intersect ENT) hover near its 52-week high of $21.39, as Russell 2000 - the small cap index, plays catch-up with the lead indices; Company to present an overview of its business, including certain preliminary 2014 results and 2015 outlook, at the J.P. Morgan 33rd Annual Conference, on January 13, 2015 at 10:00 a.m. PT. Read our research report on Intersect ENT to know more the financials and how the stock has fared, relative to its benchmark.
It's the day of reckoning for Walgreen Company (Walgreens) as shareholders prepare to vote for the second and ultimate step in Alliance Boots integration; Walgreens President and CEO Greg Wasson to retire following completion of merger. To know more about the acquisition timeline and the way forward, read our research report on Walgreens.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
